Boehringer Ingelheim International
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Prof Dr Pilar Garin-Chesa
Phone +43 1 80105-2796
Dr Marcus Kostka
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.
The Boehringer Ingelheim Regional Center Vienna is home for an integrated oncology drug discovery unit, with more than 220 scientists, technicians and support staff devoting their work to cancer research. The unit comprises several groups with expertise in biochemistry, pharmacology, chemical synthesis, structural research, assay robotics, drug discovery support (pharmacokinetics, analytics) as well as new technologies such as genomics, chemoinformatics, and bioinformatics. In particular, in vivo chemosensitivity profiling is performed for all BI drug discovery projects, including NCE and NBE drug candidates in Oncology.
For more information please visit www.boehringer-ingelheim.com